CRA recently hosted a panel discussion at the Alzheimer Europe Conference focussed on advancing policy initiatives for Alzheimer’s Disease (AD) across Europe, organised and funded by Biogen.
Building upon the findings of a recent CRA report, which synthesised insights from a roundtable of AD experts, Prioritising Alzheimer’s disease policy in Europe: Insights from oncology, the panel brought together voices from the clinical, patient, and health economic community. Several pivotal topics emerged, including the need to reframe AD as treatable and manageable, the importance of a holistic approach to policy, and value decisions and the role of EU and Member State policymakers.
Read more about prioritising Alzheimer’s Disease policy in Europe here.
